Search research articles
Contact Us
Filters
Showing results (511-520 of 688) with videos related to
Page
of 69
Sort By:
European Heart Journal
|
May 26, 2025
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial
Mario Berger, Aidan MacNamara, João Pedro Ferreira, et al.
Diabetes, Obesity & Metabolism
|
July 4, 2023
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study
Peter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Kidney International
|
December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Matthew R Weir, George L Bakris, Michael A Weber, et al.
The American Journal of Cardiology
|
January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)
Thao Huynh, Brian J Harty, Brian Claggett, et al.
Diabetes, Obesity & Metabolism
|
February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
Janet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
European Journal of Heart Failure
|
October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
João Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Circulation. Heart Failure
|
March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
Søren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Journal of Hypertension
|
July 30, 2011
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension
Amil M Shah, Carolyn S P Lam, Susan Cheng, et al.
JAMA
|
January 17, 2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Robert J Mentz, Kevin J Anstrom, Eric L Eisenstein, et al.
Page
of 69
Search research articles
Search
Showing results (511-520 of 688) with videos related to
Sort By:
Page
of 69
European Heart Journal
|
May 26, 2025
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial
Mario Berger, Aidan MacNamara, João Pedro Ferreira, et al.
Diabetes, Obesity & Metabolism
|
July 4, 2023
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study
Peter Rossing, Stefan D Anker, Gerasimos Filippatos, et al.
Kidney International Reports
|
January 10, 2022
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Kidney International
|
December 23, 2011
Renal outcomes in hypertensive Black patients at high cardiovascular risk
Matthew R Weir, George L Bakris, Michael A Weber, et al.
The American Journal of Cardiology
|
January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)
Thao Huynh, Brian J Harty, Brian Claggett, et al.
Diabetes, Obesity & Metabolism
|
February 1, 2023
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline
Janet B McGill, Rajiv Agarwal, Stefan D Anker, et al.
European Journal of Heart Failure
|
October 28, 2022
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
João Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
Circulation. Heart Failure
|
March 16, 2019
N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
Søren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Journal of Hypertension
|
July 30, 2011
The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension
Amil M Shah, Carolyn S P Lam, Susan Cheng, et al.
JAMA
|
January 17, 2023
Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Robert J Mentz, Kevin J Anstrom, Eric L Eisenstein, et al.
Page
of 69